3SBIO INC.
三生制药
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

The board of directors (the "**Board**") of 3SBio Inc. (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that Pegsiticase, a pegylated recombinant uricase (聚乙二醇化重組尿酸氧化酶) ("**SSS11**" or the "**Product**") and one of the Group's products, has received an approval of the Investigational New Drug (the "**IND**") application for clinical trials from the China Food and Drug Administration (the "**CFDA**"). SSS11 is a pegylated recombinant uricase derived from *Candida utilis*, modified by the attachment of multiple 20 kilodalton molecules of polyethylene glycol (PEG). The Group owns its global intellectual property and has licensed out the rights in the United States to Selecta Biosciences, Inc.. It has been shown to profoundly lower uric acid when administered by intravenous infusion and intramuscular injection, and was safe and well-tolerated in a pair of phase I clinical studies conducted by Selecta Biosciences, Inc. in the United States. The Group submitted the IND application to the CFDA in August 2014. The clinical trials for the Product are expected to start in early 2017.

The Group intends to develop the Product for refractory gout or tumor lysis syndrome, both of which are characterized by hyperuricemia (elevated uric acid levels). Gout is a common rheumatic disease in China, with prevalence of gout and hyperuricemia estimated to be 0.22%–0.43% and 12.1%–25.2% respectively, in the decade ending 2009, according to the article entitled "*Prevalence of Rheumatic Diseases and Disability in China*" in Rheumatology International ((2009) 29:481–490). The number of patients suffering from gout and hyperuricemia is expected to continue to grow globally due to changes in diet and lifestyle, according to the article entitled "*Progress in Diagnosis and Treatment of Gout** (痛風的診治進展)" in Journal of Internal Intensive Medicine* (內科急危重症雜誌) ((2016) 22(4):250−253).

Dr. LOU Jing, the Chairman and Chief Executive Officer of the Company commented, "We are pleased to receive the IND approval from the CFDA and look forward to moving the pegylated recombinant uricase into clinical trials in China. Refractory gout is a common disease which is difficult to treat. Currently, there lacks effective treatment for this disease. This is an exciting achievement for 3SBio's R&D team and will provide an important treatment option for gout patients. This approval will also enable us to initiate Phase I to Phase III clinical trials in one single approval. 3SBio continues to seek opportunities to develop more therapeutic biologics for refractory rheumatic diseases and other unmet medical needs, particularly in 3SBio's core therapeutic areas of oncology, rheumatology and nephrology."

By order of the Board
3SBio Inc.
Mr. LOU Jing
Chairman

Hong Kong, January 5, 2017

As at the date of this announcement, the Board comprises Mr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive directors; Mr. LIU Dong and Mr. LV Dong as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive directors.

* *For identification purposes only*